Patterns of transmitted HIV drug resistance in Europe vary by risk group

Dineke Frentz, David Van De Vijver, Ana Abecasis, Jan Albert, Osamah Hamouda, Louise Jørgensen, Claudia Kücherer, Daniel Struck, Jean Claude Schmit, Jurgen Vercauteren, Birgitta Åsjö, Claudia Balotta, Colm Bergin, Danail Beshkov, Ricardo Camacho, Bonaventura Clotet, Algirdas Griskevicius, Zehava Grossman, Andrzej Horban, Tatjana KolupajevaKlaus Korn, Leondios Kostrikis, Kirsi Liitsola Marek Linka, Claus Nielsen, Dan Otelea, Dimitrios Paraskevis, Roger Paredes, Mario Poljak, Elisabeth Puchhammer-Stöckl, Anders Sönnerborg, Danica Stanekova, Maja Stanojevic, Anne Mieke Vandamme, Charles Boucher, Annemarie Wensing

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: In Europe, a continuous programme (SPREAD) has been in place for ten years to study transmission of drug resistant HIV. We analysed time trends of transmitted drug resistance mutations (TDRM) in relation to the risk behaviour reported. Methods: HIV-1 patients newly diagnosed in 27 countries from 2002 through 2007 were included. Inclusion was representative for risk group and geographical distribution in the participating countries in Europe. Trends over time were calculated by logistic regression. Results: From the 4317 patients included, the majority was men-having-sex-with-men -MSM (2084, 48%), followed by heterosexuals (1501, 35%) and injection drug users (IDU) (355, 8%). MSM were more often from Western Europe origin, infected with subtype B virus, and recently infected (

Original languageEnglish
Article numbere94495
JournalPlosOne
Volume9
Issue number4
DOIs
Publication statusPublished - 10 Apr 2014

UN Sustainable Development Goals (SDGs)

  • SDG 3 - Good Health and Well-Being

Fingerprint Dive into the research topics of 'Patterns of transmitted HIV drug resistance in Europe vary by risk group'. Together they form a unique fingerprint.

Cite this